Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Disrupted Sphingosine-1-Phosphate Homeostasis Drives Nephrotoxicity in Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS)

View through CrossRef
AbstractSphingosine-1-phosphate lyase insufficiency syndrome (SPLIS), also known as nephrotic syndrome type 14 (NPHS14), is an autosomal recessive disorder characterized by renal, neurological, dermatological, endocrine, and immunological symptoms. This condition is caused by loss-of-function mutations in theSGPL1gene, which encodes sphingosine-1-phosphate lyase (SGPL1p/SPL), the enzyme responsible for the terminal degradation of sphingosine-1-phosphate (S1P) in sphingolipid catabolism.We investigated a novel case of SPLIS associated with a recently reportedSGPL1mutation (c.1084T>A; p.Ser362Thr). Using stable isotope flux analyses, we demonstrated in patient-derived fibroblasts andHEK293TSGPL1 knockout models that SGPL1p deficiency does not consistently result in pathological S1P accumulation.Instead, SPL-deficient cells are able to maintain steady-state S1P levels through two compensatory mechanisms:Regulation of de novo sphingolipid synthesis via the ORMDL-ceramide axis.Increased conversion of excess ceramides into glycosphingolipids.However, when steady-state conditions are disrupted—either by external sphingolipid supplementation or by impairing homeostatic control—a pathological increase in intracellular S1P occurs in SPL-deficient cells.In vivo,Sgpl1-/-mice exhibited significant urinary excretion of S1P and marked S1P enrichment in the kidneys. This pathological accumulation of S1P dysregulates cytoskeletal homeostasis, impairing renal epithelial formation. Based on these findings, we hypothesize that the reabsorption of urinary S1P contributes to toxic renal accumulation, providing an explanation for the nephrotoxicity observed in SPLIS and its association with nephrotic syndrome.Importantly, we found that the cytoskeletal disruptions could be mitigated by inhibiting the Rho-ROCK signaling pathway using the clinically approved inhibitor Fasudil. These findings illuminate the pathophysiological basis of SPLIS nephrotoxicity and propose a promising pharmacological intervention strategy.Graphical abstract
Title: Disrupted Sphingosine-1-Phosphate Homeostasis Drives Nephrotoxicity in Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS)
Description:
AbstractSphingosine-1-phosphate lyase insufficiency syndrome (SPLIS), also known as nephrotic syndrome type 14 (NPHS14), is an autosomal recessive disorder characterized by renal, neurological, dermatological, endocrine, and immunological symptoms.
This condition is caused by loss-of-function mutations in theSGPL1gene, which encodes sphingosine-1-phosphate lyase (SGPL1p/SPL), the enzyme responsible for the terminal degradation of sphingosine-1-phosphate (S1P) in sphingolipid catabolism.
We investigated a novel case of SPLIS associated with a recently reportedSGPL1mutation (c.
1084T>A; p.
Ser362Thr).
Using stable isotope flux analyses, we demonstrated in patient-derived fibroblasts andHEK293TSGPL1 knockout models that SGPL1p deficiency does not consistently result in pathological S1P accumulation.
Instead, SPL-deficient cells are able to maintain steady-state S1P levels through two compensatory mechanisms:Regulation of de novo sphingolipid synthesis via the ORMDL-ceramide axis.
Increased conversion of excess ceramides into glycosphingolipids.
However, when steady-state conditions are disrupted—either by external sphingolipid supplementation or by impairing homeostatic control—a pathological increase in intracellular S1P occurs in SPL-deficient cells.
In vivo,Sgpl1-/-mice exhibited significant urinary excretion of S1P and marked S1P enrichment in the kidneys.
This pathological accumulation of S1P dysregulates cytoskeletal homeostasis, impairing renal epithelial formation.
Based on these findings, we hypothesize that the reabsorption of urinary S1P contributes to toxic renal accumulation, providing an explanation for the nephrotoxicity observed in SPLIS and its association with nephrotic syndrome.
Importantly, we found that the cytoskeletal disruptions could be mitigated by inhibiting the Rho-ROCK signaling pathway using the clinically approved inhibitor Fasudil.
These findings illuminate the pathophysiological basis of SPLIS nephrotoxicity and propose a promising pharmacological intervention strategy.
Graphical abstract.

Related Results

Sphingosine 1-phosphate turnover in GtoPdb v.2023.1
Sphingosine 1-phosphate turnover in GtoPdb v.2023.1
S1P (sphingosine 1-phosphate) is a bioactive lipid which, after release from cells via certain transporters, acts as a ligand for a family of five S1P-specific G protein-coupled re...
Recent advances in the role of sphingosine 1‐phosphate in cancer
Recent advances in the role of sphingosine 1‐phosphate in cancer
Sphingosine 1‐phosphate (S1P) is a bioactive lipid that binds to a family of G protein‐coupled receptors (S1P1–5) and intracellular targets, such as HDAC1/2, that are functional in...
Purification and characterization of novel salt‐active acharan sulfate lyase from Bacteroides stercoris HJ‐15
Purification and characterization of novel salt‐active acharan sulfate lyase from Bacteroides stercoris HJ‐15
Salt‐active acharan sulfate lyase (no EC number) has been purified from Bacteroides stercoris HJ‐15, which was isolated from human intestinal bacteria with GAG degrading enzymes. T...
Sphingosine 1-phosphate signalling in mammalian cells
Sphingosine 1-phosphate signalling in mammalian cells
Sphingosine 1-phosphate is formed in cells in response to diverse stimuli, including growth factors, cytokines, G-protein-coupled receptor agonists, antigen, etc. Its production is...
Glutathione induces ArabidopsisPHT1;5gene via WRKY75 transcription factor to regulate phosphate homeostasis
Glutathione induces ArabidopsisPHT1;5gene via WRKY75 transcription factor to regulate phosphate homeostasis
AbstractPhosphorus is a macronutrient that regulates a wide range of physiological processes, including plant growth and development. The scarcity of bioavailable phosphate is ofte...
Sphingosine 1-phosphate signalling in cancer
Sphingosine 1-phosphate signalling in cancer
There is an increasing body of evidence demonstrating a critical role for the bioactive lipid S1P (sphingosine 1-phosphate) in cancer. S1P is synthesized and metabolized by a numbe...
Novel phosphate-based cements for clinical applications
Novel phosphate-based cements for clinical applications
This Thesis aims at the development of two novel families of inorganic phosphate cements with suitable characteristics for clinical applications in hard tissue regeneration or repl...
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
Abstract Background Liposomal amphotericin B (L-amb) is an important antifungal agent which exhibits significant rates of dose-d...

Back to Top